Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegenerative and Neuropsychiatric Disorder Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for COMT drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | COMT (S-COMT & MB-COMT Isoforms) Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Val158Met polymorphism mutants available. |
View COMT Products |
| Gene Delivery | COMT Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression validation. |
View COMT Products |
| Benchmark Ab | Anti-COMT Recombinant Antibody High-affinity sequence-verified positive control for Western Blot and ELISA development. |
View COMT Products |
| Validator | COMT siRNA Set Target-specific knockdown verification in dopaminergic cell models. |
View COMT Products |
| Related Target A | MAOB (Monoamine Oxidase B) Synergistic enzyme in dopamine catabolism; key co-target for Parkinson's disease therapeutic evaluation. |
View MAOB Products |
| Related Target B | DDC (Dopa Decarboxylase) Essential enzyme converting L-DOPA to dopamine; critical in peripheral metabolism screening networks. |
View DDC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (MB-COMT vs. S-COMT) | Distinct expression of Membrane-Bound (MB) and Soluble (S) COMT isoforms with high structural fidelity. |
| Polymorphism-Induced Variations (Val158Met) | Recombinant mutant panels (Val158 and Met158 variants) strictly verified by Mass Spectrometry. |
| Lack of Validated Controls | Recombinant benchmark control antibodies and validated small-molecule assay protocols. |
| Off-Target Screening and Subfamily Overlap | Homolog panel screening reagents with sequence verification to eliminate false-positive enzymology data. |
Live COMT R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Catechol-O-methyltransferase (COMT) remains a cornerstone in neurodegenerative drug discovery, particularly as an adjunct therapy in Parkinson's disease (PD) to prevent L-DOPA degradation. The clinical landscape is transitioning from first- and second-generation inhibitors (such as Tolcapone and Entacapone) to highly selective, peripherally restricted third-generation inhibitors (such as Opicapone) to mitigate severe hepatotoxic risks.
Simultaneously, the next wave of R&D is exploring COMT's role in the central nervous system (CNS) for the treatment of cognitive deficits in schizophrenia and bipolar disorders. The primary focus of modern drug discovery is the development of brain-penetrant inhibitors that selectively target the membrane-bound isoform (MB-COMT), which predominates in human cortical regions, while sparing peripheral S-COMT to prevent systemic side effects.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Peripheral) | Bial, Orion Pharma, Novartis | Parkinson's Disease (Adjunct) | Enzymatic Inhibition Assays (Need high-purity S-COMT and DDC/MAOB counter-screens) |
| Small Molecule (CNS-penetrant) | Academic Institutions, Biotech Startups | Schizophrenia, Cognitive Impairment | Isoform-specific binding assays (Need high-purity MB-COMT vs S-COMT recombinant proteins) |
| Gene Therapy / RNAi | Emerging Biopharma | Chronic Pain, Neuropsychiatric Disorders | Target validation and knockdown assays (Need validated COMT siRNA and Lentivirus systems) |